Optimer Is Up For Sale And Could Attract Hospital-Focused Suitors
This article was originally published in The Pink Sheet Daily
Executive Summary
The antibiotic company announced it is reviewing strategic options and that CEO Pedro Lichtinger has been replaced by Chairman Henry McKinnell. Hospital-based companies looking to beef up their portfolios with a commercial asset could drive a competitive process.
You may also be interested in...
Financings Of The Fortnight: Is Google/Calico The Start Of A Wave Of Funding Alternatives?
As survey respondents broadly expect venture capital activity to wane in the coming years, are Google and their like pointing to the next way of financing life sciences innovation? Plus news on recent financings by Civitas Therapeutics, DRI Capital, Five Prime Therapeutics and Cubist Pharmaceuticals.
Next Up For Cubist: A Future That Includes Optimer, Trius
Cubist Pharmaceuticals will strengthen its position in the challenging antibiotic market with the acquisitions of two rivals, Optimer Pharmaceuticals and Trius Therapeutics. But it was Cubist’s current strength that allowed it to get those deals done on favorable, risk-sharing terms.
Cubist’s Time To Shine: Antibiotic Specialist Acquires Optimer, Trius
Cubist will rely on its experience in infectious disease to drive growth of Dificid for Clostridium difficile infection and to launch tedizolid for skin infections, but the commercial market for new antibiotics is daunting and re-creating the success of Cubicin won’t be easy.